First, we ascertained TRIM3 downregulation in high (GBM, IDH wild-type) and lower grade (grade II diffuse astrocytoma, DA, IDH mutant) glioma samples, and TRIM3 absence in patient-derived GSCs consistent with literature (Fig. EV1B and C) (Boulay et al, 2009; Chen et al, 2014; Liu et al, 2014; Mukherjee et al, 2016). The gene discussed is IDH1; the disease is central nervous system cancer.